45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea

University of Parma
Exploring

University of California San Francisco
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.

Philipps-Universit£T Marburg
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.

Technische Universit£T M£Nchen
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.

Technische Universit£T M£Nchen
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.

Jerini
Discovery of orally available integrin alpha5beta1 antagonists.

Jerini
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.

University of Milan
Camptothecins in tumor homing via an RGD sequence mimetic.

Sigma-Tau Industrie Farmaceutiche Riunite
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.

Department of Organic Chemistry Ugo Schiff University of Firenze Via Della Lastruccia 13
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.

University of Parma
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.

Johnson & Johnson Pharmaceutical Research and Development
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.

University of Parma
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.

3-Dimensional Pharmaceuticals
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.

University of Florence
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.

Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.

Jerini
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.

Pfizer
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.

Pfizer
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.

Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.

Pfizer
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.

Johnson and Johnson Pharmaceutical Research & Development
Sortase A-mediated cyclization of novel polycyclic RGD peptides for α

Hefei Normal University
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.

Johnson & Johnson Pharmaceutical Research & Development
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.

Pfizer
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.

Glaxosmithkline
Thiophene-based vitronectin receptor antagonists.

Shire Biochem
Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.

Basf
Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.

Institut De Recherches Servier
Discovery of the first potent and selective α

University of Strathclyde
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.

University of California San Francisco
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.

Merck
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.

University of Bologna
Novel cilengitide-based cyclic RGD peptides as αvβ

Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.

Technische Universit£T M£Nchen
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Smithkline Beecham Pharmaceuticals
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α

Glaxosmithkline Medicines Research Centre
In silico studies, synthesis and binding evaluation of substituted 2-pyrrolidinones as peptidomimetics of RGD tripeptide sequence.

Paris Descartes University
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

University of Bradford
Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.

University of Nottingham
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.

Telios Pharmaceuticals
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic α

University of Strathclyde
New potent and selectiveαvβ

Jiangnan University
TrkA kinase inhibitors, compositions and methods thereof

Merck Sharp & Dohme
Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one derivatives as potential Hsp90 inhibitors.

University of Milano